As of 2025-07-16, the Intrinsic Value of Brooklyn Immunotherapeutics Inc (BTX) is 251.82 USD. This BTX valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 7.13 USD, the upside of Brooklyn Immunotherapeutics Inc is 3,431.80%.
The range of the Intrinsic Value is 216.46 - 302.96 USD
Based on its market price of 7.13 USD and our intrinsic valuation, Brooklyn Immunotherapeutics Inc (BTX) is undervalued by 3,431.80%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 216.46 - 302.96 | 251.82 | 3431.8% |
| DCF (Growth 10y) | 248.57 - 340.03 | 286.11 | 3912.8% |
| DCF (EBITDA 5y) | 260.71 - 318.32 | 289.06 | 3954.1% |
| DCF (EBITDA 10y) | 285.95 - 353.57 | 318.46 | 4366.4% |
| Fair Value | 96.13 - 96.13 | 96.13 | 1,248.19% |
| P/E | 433.44 - 674.04 | 576.26 | 7982.1% |
| EV/EBITDA | (162.55) - 405.50 | 94.14 | 1220.4% |
| EPV | (157.78) - (191.00) | (174.39) | -2545.9% |
| DDM - Stable | 121.47 - 231.44 | 176.45 | 2374.8% |
| DDM - Multi | 290.45 - 350.99 | 315.48 | 4324.7% |
| Market Cap (mil) | 13.35 |
| Beta | 4.57 |
| Outstanding shares (mil) | 1.87 |
| Enterprise Value (mil) | 13.48 |
| Market risk premium | 4.60% |
| Cost of Equity | 9.78% |
| Cost of Debt | 5.00% |
| WACC | 6.72% |